Stewart Goldman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7245023/publications.pdf

Version: 2024-02-01

74	3,701	186265 28	133252 59
papers	citations	h-index	g-index

76	76	76	5400
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor. Journal of Clinical Oncology, 2009, 27, 385-389.	1.6	397
2	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
3	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€“Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654.	1.6	368
4	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncology, The, 2019, 20, 1011-1022.	10.7	315
5	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
6	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology, 2017, 19, 1135-1144.	1.2	236
7	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
8	Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 2464-2471.	1.6	136
9	Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncology, 2016, 18, 1319-1325.	1.2	108
10	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro-Oncology, 2017, 19, 1279-1280.	1.2	93
11	Self-Reported Worries Among Long-Term Survivors of Childhood Cancer and Their Peers. Journal of Psychosocial Oncology, 1998, 16, 1-23.	1.2	90
12	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82
13	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncology, 2018, 20, 13-23.	1.2	74
14	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro-Oncology, 2016, 18, now106.	1.2	73
15	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	8.2	70
16	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro-Oncology, 2019, 21, 537-546.	1.2	61
17	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on â€œHead Startâ€•III: a multi-institutional, prospective clinical trial. Neuro-Oncology, 2020, 22, 1862-1872.	1.2	57
18	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2019, 25, 5572-5583.	7.0	52

#	Article	IF	Citations
19	Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients. Neuro-Oncology, 2019, 21, 934-943.	1.2	51
20	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. Neuro-Oncology, 2020, 22, 1647-1657.	1.2	51
21	REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma. Molecular Cancer Therapeutics, 2012, 11, 1713-1723.	4.1	47
22	Cabozantinib for neurofibromatosis type 1â€“related plexiform neurofibromas: a phase 2 trial. Nature Medicine, 2021, 27, 165-173.	30.7	46
23	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1â€“associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-Oncology, 2020, 22, 1527-1535.	1.2	45
24	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro-Oncology, 2014, 16, 1554-1559.	1.2	44
25	MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Molecular Cancer Research, 2016, 14, 984-993.	3.4	38
26	Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget, 2014, 5, 8442-8451.	1.8	35
27	HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. Scientific Reports, 2018, 8, 1211.	3.3	30
28	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Molecular Cancer Research, 2018, 16, 32-46.	3.4	29
29	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. Journal of Neuro-Oncology, 2018, 136, 475-484.	2.9	22
30	Transcriptional repressor REST drives lineage stageâ€“specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. Science Signaling, 2019, 12, .	3.6	19
31	Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Current Problems in Cancer, 2021, 45, 100777.	2.0	17
32	Using the Patientâ€Reported Outcomes Measurement Information System (PROMIS) to measure symptom burden reported by patients with brain tumors. Pediatric Blood and Cancer, 2019, 66, e27526.	1.5	15
33	Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro-Oncology, 2020, 22, 1696-1704.	1.2	14
34	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology, 2022, 24, 1178-1190.	1.2	13
35	Computerized Adaptive Testing in Pediatric Brain Tumor Clinics. Journal of Pain and Symptom Management, 2017, 54, 289-297.	1.2	12
36	REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget, 2018, 9, 5233-5250.	1.8	12

#	Article	IF	Citations
37	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. Neuro-Oncology, 2022, 24, 1950-1961.	1.2	12
38	A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. BioTechniques, 2016, 60, 43-6.	1.8	11
39	A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients. Child's Nervous System, 2016, 32, 475-483.	1.1	11
40	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma. Neurosurgery, 2020, 87, E680-E688.	1.1	11
41	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. Journal of Clinical Oncology, 2014, 32, 10065-10065.	1.6	10
42	Parent-reported cognitive function is associated with leukoencephalopathy in children with brain tumors. Quality of Life Research, 2017, 26, 2541-2550.	3.1	9
43	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1â€associated optic pathway gliomas in children. Pediatric Blood and Cancer, 2021, 68, e28833.	1.5	9
44	Characteristics of patients â‰¥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	1.2	9
45	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro-Oncology, 2022, 24, 821-833.	1.2	9
46	Getting serious about the early-life epilepsies. Neurology, 2018, 90, 842-848.	1.1	8
47	Pediatric Brain Metastasis from Extraneural Malignancies: A Review. Cancer Treatment and Research, 2007, 136, 143-168.	0.5	8
48	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. Journal of Clinical Oncology, 2013, 31, 2035-2035.	1.6	8
49	Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. Journal of Neuro-Oncology, 2009, 95, 289-292.	2.9	7
50	A phase 1/2 doseâ€finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood and Cancer, 2018, 65, e27217.	1.5	6
51	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology, 2023, 25, 199-210.	1.2	6
52	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Journal of Neuro-Oncology, 2020, 149, 437-445.	2.9	5
53	Characteristics of children â‰¤36 months of age with DIPG: A report from the international DIPG registry. Neuro-Oncology, 2022, 24, 2190-2199.	1.2	4
54	LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial. Neuro-Oncology, 2022, 24, i88-i88.	1.2	3

#	Article	IF	Citations
55	Symptom burden trajectories experienced by patients with brain tumors. Cancer, 2020, 126, 3341-3351.	4.1	2
56	New insights into malignant cell survival mechanisms in medulloblastoma. Cancer Cell & Microenvironment, 2014, 1, .	0.8	2
57	A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.. Journal of Clinical Oncology, 2013, 31, 2036-2036.	1.6	2
58	OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO). Neuro-Oncology, 2022, 24, i148-i148.	1.2	2
59	DIPG-33. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. Neuro-Oncology, 2018, 20, i55-i55.	1.2	1
60	QOL-11. SYMPTOM BURDEN EXPERIENCED BY CHILDREN WITH BRAIN TUMORS AND ITS INFLUENTIAL FACTORS. Neuro-Oncology, 2018, 20, i159-i159.	1.2	1
61	Benign skull and subdural lesions in patients with prior medulloblastoma therapy. Child's Nervous System, 2021, 37, 359-366.	1.1	1
62	Retinoblastoma associated with congenital hypotonia: A case report and review of the literature. Journal of Pediatric Neurology, 2015, 04, 265-270.	0.2	0
63	DIPG-36. NOVEL THERAPEUTIC APPROACHES USING NANOLIPOSMAL SN-38 FOR THE TREATMENT OF HUMAN BRAINSTEM GLIOMA. Neuro-Oncology, 2017, 19, iv13-iv13.	1.2	0
64	SCDT-20. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. Neuro-Oncology, 2017, 19, vi269-vi269.	1.2	0
65	RONC-22. IMPACT OF RADIOTHERAPY MODALITY ON NEUROPSYCHOLOGICAL OUTCOMES OF PEDIATRIC BRAIN TUMOR PATIENTS. Neuro-Oncology, 2018, 20, i179-i179.	1.2	0
66	PDTM-42. TARGETED INHIBITION OF BET BROMODOMAIN AND JMJD3 PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, vi212-vi213.	1.2	0
67	Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future. Molecular Biology Reports, 2021, 48, 7537-7544.	2.3	0
68	Parent-reported cognition and its clinical applications in pediatric oncology.. Journal of Clinical Oncology, 2012, 30, 9532-9532.	1.6	0
69	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. Journal of Clinical Oncology, 2020, 38, 2503-2503.	1.6	0
70	DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii285-iii286.	1.2	0
71	IMG-04. RESPONSE ASSESSMENT IN PEDIATRIC HIGH-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY WORKING GROUP. Neuro-Oncology, 2020, 22, iii355-iii355.	1.2	0
72	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-Oncology, 2022, 24, i54-i54.	1.2	0

#	Article	IF	Citations
73	RARE-13. Clinical management and functional and survival outcomes in pediatric craniopharyngioma, a patient and family perspective. Neuro-Oncology, 2022, 24, i12-i12.	1.2	0
74	RARE-17. Multi-institutional craniopharyngioma cohort highlights need for more comprehensive data collection on comorbidities and quality of life. Neuro-Oncology, 2022, 24, i13-i13.	1.2	0